These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Adverse events during immunotherapy in Slovenian patients with metastatic melanoma reveal a positive correlation with better treatment outcomes. Mesti T; Ceplak Mencin V; Mileva Boshkoska B; Ocvirk J Radiol Oncol; 2021 May; 55(3):354-361. PubMed ID: 33939899 [TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis. Koch EAT; Petzold A; Wessely A; Dippel E; Gesierich A; Gutzmer R; Hassel JC; Haferkamp S; Hohberger B; Kähler KC; Knorr H; Kreuzberg N; Leiter U; Loquai C; Meier F; Meissner M; Mohr P; Pföhler C; Rahimi F; Schadendorf D; Schell B; Schlaak M; Terheyden P; Thoms KM; Schuler-Thurner B; Ugurel S; Ulrich J; Utikal J; Weichenthal M; Ziller F; Berking C; Heppt MV; On Behalf Of The German Dermatologic Cooperative Oncology Group DeCOG Committee Ocular Melanoma Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34283061 [TBL] [Abstract][Full Text] [Related]
6. Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial. Koch EAT; Petzold A; Wessely A; Dippel E; Eckstein M; Gesierich A; Gutzmer R; Hassel JC; Knorr H; Kreuzberg N; Leiter U; Loquai C; Meier F; Meissner M; Mohr P; Pföhler C; Rahimi F; Schadendorf D; Schlaak M; Thoms KM; Ugurel S; Utikal J; Weichenthal M; Schuler-Thurner B; Berking C; Heppt MV Front Med; 2023 Oct; 17(5):878-888. PubMed ID: 37432641 [TBL] [Abstract][Full Text] [Related]
7. The Role of Immune Checkpoint Blockade in Uveal Melanoma. Wessely A; Steeb T; Erdmann M; Heinzerling L; Vera J; Schlaak M; Berking C; Heppt MV Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32013269 [TBL] [Abstract][Full Text] [Related]
8. Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment. Petzold A; Steeb T; Wessely A; Koch EAT; Vera J; Berking C; Heppt MV Cancer Treat Rev; 2023 Apr; 115():102543. PubMed ID: 36931146 [TBL] [Abstract][Full Text] [Related]
9. Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles. Ye W; Olsson-Brown A; Watson RA; Cheung VTF; Morgan RD; Nassiri I; Cooper R; Taylor CA; Akbani U; Brain O; Matin RN; Coupe N; Middleton MR; Coles M; Sacco JJ; Payne MJ; Fairfax BP Br J Cancer; 2021 May; 124(10):1661-1669. PubMed ID: 33723392 [TBL] [Abstract][Full Text] [Related]
13. Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy. Watson AS; Goutam S; Stukalin I; Ewanchuk BW; Sander M; Meyers DE; Pabani A; Cheung WY; Heng DYC; Cheng T; Monzon JG; Navani V JAMA Netw Open; 2022 Dec; 5(12):e2245596. PubMed ID: 36480204 [TBL] [Abstract][Full Text] [Related]
14. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma. Klemen ND; Wang M; Rubinstein JC; Olino K; Clune J; Ariyan S; Cha C; Weiss SA; Kluger HM; Sznol M J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32209601 [TBL] [Abstract][Full Text] [Related]
15. Clinical determinants of long-term survival in metastatic uveal melanoma. Koch EAT; Petzold A; Wessely A; Dippel E; Erdmann M; Heinzerling L; Hohberger B; Knorr H; Leiter U; Meier F; Mohr P; Rahimi F; Schell B; Schlaak M; Terheyden P; Schuler-Thurner B; Ugurel S; Utikal J; Vera J; Weichenthal M; Ziller F; Berking C; Heppt MV Cancer Immunol Immunother; 2022 Jun; 71(6):1467-1477. PubMed ID: 34709438 [TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review. Heppt MV; Steeb T; Schlager JG; Rosumeck S; Dressler C; Ruzicka T; Nast A; Berking C Cancer Treat Rev; 2017 Nov; 60():44-52. PubMed ID: 28881222 [TBL] [Abstract][Full Text] [Related]
17. Determinants of overall survival in patients with metastatic uveal melanoma. Demkowicz P; Pointdujour-Lim R; Miguez S; Lee Y; Jones BSCL; Barker CA; Bosenberg M; Abramson DH; Shoushtari AN; Kluger H; Francis JH; Sznol M; Bakhoum MF Cancer; 2023 Oct; 129(20):3275-3286. PubMed ID: 37382208 [TBL] [Abstract][Full Text] [Related]
18. Inflammatory markers in autoimmunity induced by checkpoint inhibitors. Husain B; Kirchberger MC; Erdmann M; Schüpferling S; Abolhassani AR; Fröhlich W; Berking C; Heinzerling L J Cancer Res Clin Oncol; 2021 Jun; 147(6):1623-1630. PubMed ID: 33837821 [TBL] [Abstract][Full Text] [Related]
19. Anti-PD-1 antibodies in metastatic uveal melanoma: a treatment option? Bender C; Enk A; Gutzmer R; Hassel JC Cancer Med; 2017 Jul; 6(7):1581-1586. PubMed ID: 28639409 [TBL] [Abstract][Full Text] [Related]
20. Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy. Bai X; Hu J; Betof Warner A; Quach HT; Cann CG; Zhang MZ; Si L; Tang B; Cui C; Yang X; Wei X; Pallan L; Harvey C; Manos MP; Ouyang O; Kim MS; Kasumova G; Cohen JV; Lawrence DP; Freedman C; Fadden RM; Rubin KM; Sharova T; Frederick DT; Flaherty KT; Rahma OE; Long GV; Menzies AM; Guo J; Shoushtari AN; Johnson DB; Sullivan RJ; Boland GM Clin Cancer Res; 2021 Nov; 27(21):5993-6000. PubMed ID: 34376536 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]